Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical Research

Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

International Journal of Obesity volume 47, pages 883–892 (2023)Cite this article

Subjects

Abstract

Objectives

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes. We performed a meta-analysis to assess tirzepatide’s weight reduction efficacy and safety.

Methods

We searched PubMed, Embase, and Cochrane for randomized controlled trials published from inception to July 2022, comparing tirzepatide with placebo for the co-primary endpoints of absolute and percent change in weight. Mean difference (MD) and odds ratio (OR) were calculated for continuous and binary outcomes, respectively. Review Manager 5.4.1 and RStudio were used for the statistical analysis, and RoB-2 (Cochrane) to assess the risk of bias.

Results

Of 397 search results, 6 studies (4036 participants) ranging from 12 to 72 weeks were included. Pooled analysis showed that tirzepatide 5 mg, 10 mg, and 15 mg were more effective than placebo, with MD in body weight of −7.7 kg (95% CI −11.0, −4.4; p < 0.001), −11.6 kg (95% CI −18.8, −4.3; p = 0.002), and −11.8 kg (95% CI −17.4, -6.2; p < 0.001), respectively, and MD in percent change in weight of −8.1% (95% CI −11.0, −5.2; p < 0.001), −11.9% (95% CI −18.1, −5.6; p < 0.001), and -12.4% (95% CI −17.2, −7.5; p < 0.001), respectively. Tirzepatide also reduced BMI and waist circumference. Adverse events were more common with tirzepatide with respect to nausea (OR 4.2; 95% CI 2.4, 7.5; p < 0.001), vomiting (OR 7.0; 95% CI 4.3, 11.4; p < 0.001), and diarrhea (OR 2.8; 95% CI 1.6, 4.9; p < 0.001) (15 mg dose), when compared with placebo.

Conclusions

The results support that tirzepatide leads to substantial weight reduction and constitutes a valuable therapeutic option for weight management, despite an increase in gastrointestinal symptoms.

Protocol registration

CRD42022348576.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: PRISMA flow diagram of study screening and selection.
Fig. 2: Comparison of tirzepatide versus placebo for absolute and percent weight change.
Fig. 3: Comparison of tirzepatide versus placebo for BMI and waist circumference change.
Fig. 4

Data availability

This meta-analysis is based on data extracted from previously published research that belongs to the public domain. The authors do not have access to individual study’s patient-level data, and encourage readers interested in these types of data to contact the corresponding author from each of the studies here included.

References

  1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13–27.

    Article  Google Scholar 

  2. Cavalcanti OB, Barquera S, Baur L, Busch V, Buse K, Dietz B, et al. World Obesity Atlas 2022. In: World Obesity Day. World Obesity Federation. 2022. https://www.worldobesityday.org/assets/downloads/World_Obesity_Atlas_2022_WEB.pdf.

  3. World Health Organization. Obesity and Overweight. 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

  4. Yanovski SZ, Yanovski JA. Progress in Pharmacotherapy for Obesity. JAMA. 2021;326:129–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45:S113–S124.

    Article  Google Scholar 

  6. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12:143–57.

    Article  CAS  PubMed  Google Scholar 

  7. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Geisler CE, Antonellis MP, Trumbauer W, Martin JA, Coskun T, Samms RJ, et al. Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents. Diabetes Obes Metab. 2023;25:56–67.

    Article  CAS  PubMed  Google Scholar 

  9. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27:4315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–16.

    Article  CAS  PubMed  Google Scholar 

  11. Ankit Rohatgi. Webplotdigitizer: Version 4.6. 2022. https://automeris.io/WebPlotDigitizer.

  12. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3. 2022. https://training.cochrane.org/handbook.

  13. Lawrance R, Degtyarev E, Griffiths P, Traks P, Lau H, D’Alessio D, et al. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? J Patient Rep Outcomes. 2020;4:68.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Committee for Medicinal Products for Human Use. Step 5. In: ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. European Medicines Agency. 2020. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf.

  15. Good Clinical Practice Network. 1. Glossary. 2022. https://ichgcp.net/1-glossary.

  16. Higgins JP, Savovic J, Page MJ, Sterne JA, Development Group for RoB 2.0. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) https://www.bristol.ac.uk/media-library/sites/social-community-medicine/images/centres/cresyda/RoB2-0_indiv_main_guidance.pdf 2016.

  17. Schünemann H, Brożek J, Guyatt G, Oxman A GRADE handbook for grading quality of evidence and strength of recommendations. 2013. https://gdt.gradepro.org/app/handbook/handbook.html.

  18. McMaster University and Evidence Prime. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. 2022. www.gradepro.org.

  19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    Article  PubMed  PubMed Central  Google Scholar 

  20. The Cochrane Collaboration. Review Manager (RevMan): Version 5.4.1. 2020. https://training.cochrane.org/online-learning/core-software/revman.

  21. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:39.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Expert panel report: Guidelines. (2013) for the management of overweight and obesity in adults. Obesity. 2014;22:S41–10. https://doi.org/10.1002/oby.20660

    Article  Google Scholar 

  23. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–56.

    Article  PubMed  Google Scholar 

  24. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503–15.

    Article  PubMed  Google Scholar 

  25. Kang H. Trial sequential analysis: novel approach for meta-analysis. Anesth Pain Med (Seoul). 2021;16:138–50.

    Article  PubMed  Google Scholar 

  26. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C User Manual for Trial Sequential Analysis (TSA). In: Copenhagen Trial Unit, Center for Clinical Intervention Research. 2017. https://ctu.dk/tsa/.

  27. Furihata K, Mimura H, Urva S, Oura T, Ohwaki K, Imaoka T. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022;24:239–46.

    Article  CAS  PubMed  Google Scholar 

  28. Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22:1886–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Wilson JM, Nikooienejad A, Robins DA, Roell WC, Riesmeyer JS, Haupt A, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22:2451–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2021 Jul 17;398(10296):212]. Lancet. 2021;398:143–55.

    Article  CAS  PubMed  Google Scholar 

  31. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327:534–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Razzaki TS, Weiner A, Shukla AP. Tirzepatide: Does the Evidence to Date Show Potential for the Treatment of Early Stage Type 2 Diabetes? Ther Clin Risk Manag. 2022;18:955–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–93.

    Article  CAS  PubMed  Google Scholar 

  34. Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22:938–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10:418–29.

    Article  CAS  PubMed  Google Scholar 

  36. Yu Y, Hu G, Yin S, Yang X, Zhou M, Jian W. Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis. Front. Cardiovasc. Med. 2022;9:990182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143:e984–e1010.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020;16:177–89.

    Article  PubMed  PubMed Central  Google Scholar 

  39. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. on behalf of the American Diabetes Association, 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46:S128–39.

    Article  CAS  PubMed  Google Scholar 

  40. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017;6:187–94.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65:1251–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials. Pharmaceuticals (Basel). 2021;14:991.

    Article  CAS  PubMed  Google Scholar 

  43. Dutta D, Surana V, Singla R, Aggarwal S, Sharma M. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian J Endocrinol Metab. 2021;25:475–89.

    Article  CAS  PubMed  Google Scholar 

  44. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398:1811–24.

    Article  PubMed  Google Scholar 

  45. Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, Gulliford MC. Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records. Am J Pub Health. 2015;105:e54–9.

    Article  Google Scholar 

  46. Si K, Hu Y, Wang M, Apovian CM, Chavarro JE, Sun Q. Weight loss strategies, weight change, and type 2 diabetes in US health professionals: A cohort study. PLoS Med. 2022;19:e1004094.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Funding

No funding source was involved in the data collection, statistical analyses, and writing of the paper. FM is supported by a T32-postdoctoral Training Grant in Cardiovascular Research from the National Heart, Lung, and Blood Institute (T32 HL007604).

Author information

Author notes

  1. These authors contributed equally: Filipe Azevedo Moura, Vladimir Vitalievich Rafalskiy.

Authors and Affiliations

  1. Division of Medicine, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, Brazil

    Yasmin Luz Lima de Mesquita

  2. Division of Medicine, Immanuel Kant Baltic Federal University, Kaliningrad, Kaliningrad Oblast, Russia

    Izabela Pera Calvi, Sara Almeida Cruz & Vladimir Vitalievich Rafalskiy

  3. Division of Medicine, Universitat Internacional de Catalunya, Barcelona, Catalunya, Spain

    Isabela Reis Marques

  4. Division of Pulmonary and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Eduardo Messias Hirano Padrao

  5. Division of Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Pedro Emanuel de Paula Carvalho

  6. Division of Medicine, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil

    Caroliny Hellen Azevedo da Silva

  7. Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Rhanderson Cardoso & Filipe Azevedo Moura

  8. TIMI study group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston MA, USA

    Filipe Azevedo Moura

Authors
  1. Yasmin Luz Lima de Mesquita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Izabela Pera Calvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabela Reis Marques
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sara Almeida Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduardo Messias Hirano Padrao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pedro Emanuel de Paula Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caroliny Hellen Azevedo da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rhanderson Cardoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Filipe Azevedo Moura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vladimir Vitalievich Rafalskiy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YM conceived and designed the study. YM and CS designed the review protocol and participated in the database searches and screening process. YM extracted data and performed all statistical analyses. YM, IC, IM, and SC, interpreted the results of the analysis. EP created the TSA. PC did the leave-one-out sensitivity analysis, Baujat plot and the meta-regressions. YM wrote the initial draft of the manuscript, which was then edited by IC, IM, SC, EP, PC, CS, and FM. Feedback was given by FM, RC, and VR on the final draft. All authors read and approved the final manuscript. All authors agree to be accountable for all aspects of the work. YM is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for its accuracy and integrity.

Corresponding author

Correspondence to Yasmin Luz Lima de Mesquita.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Mesquita, Y.L.L., Pera Calvi, I., Reis Marques, I. et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials. Int J Obes 47, 883–892 (2023). https://doi.org/10.1038/s41366-023-01337-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41366-023-01337-x

Search

Advanced search

Quick links